Get the Stockscreener App
5.14
0.39%
-0.02
After Hours:
5.35
0.21
+4.09%
Abeona Therapeutics Inc stock is traded at $5.14, with a volume of 2.09M.
It is down -0.39% in the last 24 hours and up +0.39% over the past month.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
See More
Previous Close:
$5.16
Open:
$5.24
24h Volume:
2.09M
Relative Volume:
1.82
Market Cap:
$278.54M
Revenue:
$400.00K
Net Income/Loss:
$82.35M
P/E Ratio:
4.4109
EPS:
1.1653
Net Cash Flow:
$-82.36M
1W Performance:
+4.05%
1M Performance:
+0.39%
6M Performance:
-21.29%
1Y Performance:
+1.98%
1-Day Range:
$5.105
$5.32
1-Week Range:
$4.73
$5.32
52-Week Range:
$3.9328
$7.5401
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
5.14 | 279.63M | 400.00K | 82.35M | -82.36M | 1.1653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.17 | 117.08B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
772.03 | 82.63B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
742.79 | 45.82B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.38 | 42.92B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
305.39 | 33.54B | 5.36B | 287.73M | 924.18M | 2.5229 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Mar-05-25 | Initiated | Oppenheimer | Outperform |
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Stifel | Buy |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Oppenheimer Maintains Outperform on Abeona Therapeutics (ABEO) PT $22 March 2026 - Meyka
Oppenheimer raises Abeona Therapeutics price target on launch progress - Investing.com
Abeona Therapeutics Announces Momentum in ZEVASKYN® Gene Therapy Launch for Recessive Dystrophic Epidermolysis Bullosa (RDEB) - Minichart
Abeona reports progress in ZEVASKYN gene therapy launch - Investing.com Nigeria
Abeona Therapeutics (ABEO) Progress with Zevaskyn Launch - GuruFocus
Abeona Accelerates ZEVASKYN Commercial Momentum and Market Access - TipRanks
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch - The Manila Times
Abeona Therapeutics reports early commercial momentum and payer coverage for ZEVASKYN launch - TradingView
Gene therapy ZEVASKYN gains broad insurance coverage for RDEB patients - Stock Titan
Abeona Therapeutics Announces Date of Fourth Quarter, Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference - marketscreener.com
Abeona Therapeutics Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference - Bitget
Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference - marketscreener.com
Abeona Therapeutics® Announces Date of Fourth Quarter / - GlobeNewswire
Avoiding Lag: Real-Time Signals in (ABEO) Movement - Stock Traders Daily
Abeona Therapeutics Inc. $ABEO Shares Sold by Western Standard LLC - MarketBeat
Abeona Therapeutics Inc. (ABEO) Stock Analysis: Exploring a Potential 289% Upside in Gene Therapy Innovations - DirectorsTalk Interviews
Abeona Therapeutics (NASDAQ:ABEO) Stock Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
ABEO Should I Buy - Intellectia AI
Analysts Are Bullish on These Healthcare Stocks: Vanda (VNDA), Abeona Therapeutics (ABEO) - The Globe and Mail
Is Abeona Therapeutics Inc. a strong growth stockInflation Watch & Safe Entry Momentum Tips - mfd.ru
Big Picture: Does Abeona Therapeutics Inc have strong EBITDA marginsJuly 2025 EndofMonth & Safe Entry Zone Tips - baoquankhu1.vn
Discipline and Rules-Based Execution in ABEO Response - Stock Traders Daily
Abeona Therapeutics Inc. (NASDAQ:ABEO) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Epidermolysis Bullosa Clinical Trial Pipeline Robust as 20+ - openPR.com
Is Abeona Therapeutics Inc. (PCJ) stock undervalued by metricsJuly 2025 Price Swings & Low Drawdown Trading Strategies - mfd.ru
Published on: 2026-02-14 07:33:27 - mfd.ru
ABEO SEC FilingsAbeona Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Is Abeona Therapeutics Inc. stock overvalued or fairly priced2025 Buyback Activity & Fast Moving Stock Watchlists - mfd.ru
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Seven new Abeona hires get 3-year stock grants as inducement - Stock Titan
Behavioral Patterns of ABEO and Institutional Flows - Stock Traders Daily
Abeona Therapeutics Inc. (ABEO) Investor Outlook: Unpacking A 306% Potential Upside - DirectorsTalk Interviews
Abeona Therapeutics (NASDAQ:ABEO) Director Sells 20,070 Shares - MarketBeat
Abeona sells Rare Pediatric Disease PRV for $155M - MSN
Crombez Eric sells Abeona Therapeutics (ABEO) shares for $82895 By Investing.com - Investing.com Nigeria
Abeona Therapeutics director sells $75k in stock By Investing.com - Investing.com South Africa
Crombez Eric sells Abeona Therapeutics (ABEO) shares for $82895 - Investing.com
Abeona Therapeutics director sells $75k in stock - Investing.com
Abeona Therapeutics (NASDAQ:ABEO) Director Eric Crombez Sells 16,284 Shares - MarketBeat
Abeona Therapeutics (NASDAQ:ABEO) Director Mark Alvino Sells 2,000 Shares - MarketBeat
Leila Alland Sells 18,065 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock - MarketBeat
Insider-Favored Growth Companies To Watch February 2026 - simplywall.st
Merger Talk: Is Abeona Therapeutics Inc in a bullish channelSwing Trade & Stock Timing and Entry Methods - baoquankhu1.vn
Sentiment Watch: How does FVNNU score in quality rankingsBond Market & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Dividend Watch: How does CBTJ correlate with NasdaqWeekly Gains Summary & Accurate Buy Signal Notifications - baoquankhu1.vn
Is Abeona Therapeutics Inc. stock forming a cup and handleJuly 2025 Highlights & Reliable Volume Spike Alerts - mfd.ru
Abeona Therapeutics Inc. (ABEO) Stock Analysis: Exploring a 327% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
(ABEO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Abeona Therapeutics (NASDAQ:ABEO) Insider Madhav Vasanthavada Sells 12,610 Shares of Stock - MarketBeat
Abeona Therapeutics Inc. (NASDAQ:ABEO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Abeona Therapeutics CEO Seshadri Vishwas sells $372k in shares By Investing.com - Investing.com India
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.28%
17.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):